Reuters - Video

Edition: US | UK | IN | CN | JP

video Finance Videos

Wall Street gets Fed reality check
Wall Street gets Fed reality check - 01:51
Reuters Today: Spanish yields seen rising at auction
Reuters Today: Spanish yields seen rising at auction - 06:21
Surprise services boost points to UK recovery
Surprise services boost points to UK recovery - 02:54
Breakingviews: Do as I say, not as I do – German wages
Breakingviews: Do as I say, not as I do – German wages - 05:04
Market Pulse: Spain under fire as investors shun bond sale
Market Pulse: Spain under fire as investors shun bond sale - 03:28
Myanmar's Kyat begins managed float
Myanmar's Kyat begins managed float - 01:59
ASEAN: territorial code of conduct draft by year-end
ASEAN: territorial code of conduct draft by year-end - 01:48
U.S. Morning Call: Stock futures down, JPMorgan to be fined
U.S. Morning Call: Stock futures down, JPMorgan to be fined - 02:08
EMEA Day Ahead:: Thursday
EMEA Day Ahead:: Thursday - 03:13
3XSQ: Customer funds in question; royal return
3XSQ: Customer funds in question; royal return - 05:44
Still cashing in? Hirst retrospective
Still cashing in? Hirst retrospective - 02:32
World's biggest car delivery center
World's biggest car delivery center - 02:41

Actelion and J&J close to sealing deal?

Friday, January 06, 2017 - 00:49

Johnson & Johnson and Actelion are reported to be asking Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm. Ciara Lee reports.

▲ Hide Transcript

▶ View Transcript

A deal is edging closer - if newspaper headlines are to be believed anyway. Johnson & Johnson and Actelion have reportedly asked Switzerland's takeover board about the viability of a deal. Johnson & Johnson would acquire Actelion while separating its commercialised portfolio from its research and development assets. The panel's preliminary review is apparently ongoing, one Swiss paper said. The Swiss takeover board, which determines whether a deal meets legal requirements did not immediately comment. The proposed deal structure would allow U.S. healthcare company J&J to acquire Swiss biotech firm Actelion with a cash offer in the region of $260 per share. That's a little more than what it had offered when it walked away from negotiations in December.

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

Close

Actelion and J&J close to sealing deal?

Friday, January 06, 2017 - 00:49